Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indocyanine green to assess vascularity of ileal conduit anastomosis during pelvic exenteration
2024-518783-13-00Phase 2Authorised
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indocyanine green in Cervical Cancer (CC), Vulval carcinoma, vaginal cancer and 1 more, sponsored by Policlinico Gemelli. Primary endpoint: Overall rate of benign uretero-enteric stricture. Planned start Nov 2024; status: authorised.
02
Drugs
indocyanine green
03
Conditions
Cervical Cancer (CC)Vulval carcinomavaginal cancerendometrial cancer (EC)
Beyond the preview
Go deeper on 2024-518783-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518783-13-00.